 Jounce Therapeutics Inc. JNCEshares jumped more than 70 in after-hours trading Tuesday, following an announcement that Gilead Sciences Inc. GILDwould completely acquire rights to an immunotherapy drug from Jounce. Gilead said it would buy out its remaining obligations under a licensing agreement executed in 2020 between the two companies and acquire intellectual property and rights ... The post : Jounce stock bounces more than 70 after Gilead acquires immunotherapy drug appeared first on Forex... 